Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Mcbride, A."'
Autor:
Lee, Nancy Y., Sherman, Eric J., Schöder, HeiKo, Wray, Rick, Boyle, Jay O., Singh, Bhuvanesh, Grkovski, Milan, Paudyal, Ramesh, Cunningham, Louise, Zhang, Zhigang, Hatzoglou, Vaios, Katabi, Nora, Diplas, Bill H., Han, James, Imber, Brandon S., Pham, Khoi, Yu, Yao, Zakeri, Kaveh, McBride, Sean M., Kang, Jung J.
Publikováno v:
Journal of Clinical Oncology; 3/10/2024, Vol. 42 Issue 8, p940-950, 18p
Autor:
Niazi, Tamim, Nguyen, Paul L., Williams, Scott, Stockler, Martin R., Martin, Andrew James, Horvath, Lisa, Thomas, Hayley, Zebic, Danka Sinikovic, Roncolato, Felicia, Lim, Tee, Jose, Chakiath, Martin, Jarad, Chung, Hans T., Ebacher, Annie, Morgan, Scott C., Hughes, Simon, McBride, Sean Matthew, Kelly, Paul J., Davis, Ian D., Sweeney, Christopher
Publikováno v:
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p328-328, 97p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Eric J. Sherman, Jahan Aghalar, Nancy Y. Lee, Sean McBride, Robert J. Young, Robert A. Lefkowitz, Zhigang Zhang, C. Jillian Tsai, Shrujal S. Baxi, Lara Dunn, Loren S. Michel, Alan L. Ho, David G. Pfister, Juliana Eng, D. Spielsinger, Jessica Flynn, Nadeem Riaz, Daniel C. McFarland, Wanqing Iris Zhi
Publikováno v:
Journal of Clinical Oncology. 39:30-37
PURPOSE The objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherap
Autor:
Kaitlyn McBride, Sophie Snyder
Publikováno v:
Journal of Clinical Oncology. 40:413-413
413 Background: Chimeric antigen receptor (CAR) T cell therapy is a high-value innovative therapy for patients diagnosed with diffuse large B cell lymphoma (LBCL). The Federal Drug Administration (FDA) has approved three CAR T-cell therapies for thes
Publikováno v:
Journal of Clinical Oncology. 40:19-19
19 Background: MCL is an aggressive form of non-Hodgkin’s lymphoma with an incidence of 1 in 200,000 in the United States. Limited evidence exists on real-world tx utilization, costs, and survival outcomes associated with MCL among older pts in the
Autor:
Emily Zhi-Yun Keung, Elise F Nassif, Heather Y. Lin, Alexander J. Lazar, Keila E Torres, Wei-Lien Wang, Beverly Ashleigh Guadagnolo, Andrew Justin Bishop, Kelly Hunt, Barry W. Feig, Justin E. Bird, Valerae O. Lewis, Ravin Ratan, Shreyaskumar Patel, Monika Zelazowska, Bin Liu, Kevin McBride, Jennifer Ann Wargo, Christina Lynn Roland, Neeta Somaiah
Publikováno v:
Journal of Clinical Oncology. 40:LBA11501-LBA11501
LBA11501 Background: We conducted a randomized, phase II non-comparative trial evaluating the efficacy of neoadjuvant ICB [nivolumab or ipilimumab/nivolumab] in patients (pts) with surgically resectable retroperitoneal DDLPS or extremity/truncal UPS
Autor:
Lara Dunn, Eric Jeffrey Sherman, Alan Loh Ho, Ian Ganly, Nadeem Riaz, Luc Morris, Kin Wai (Tony) Hung, Anuja Kriplani, Jennifer R. Cracchiolo, Marc Cohen, Jay Boyle, Snehal G. Patel, Sofia Haque, Nora Katabi, Ronald A Ghossein, Sean Matthew McBride, Loren S. Michel, Richard J. Wong, Nancy Y. Lee, David G. Pfister
Publikováno v:
Journal of Clinical Oncology. 40:TPS6109-TPS6109
TPS6109 Background: Definitive treatment of locally advanced HNSCC can require radical surgery and reconstruction often resulting in unacceptable functional consequences. Radiotherapy, often with concurrent chemotherapy, is administered postoperative
Autor:
Tara L. Lin, Robyn Wood, Tammy Ham, Taegen Sullivan, Sangita Bhattacharyya, Prasad Dandawate, Shrikant Anant, Marianne T Santaguida, Na Zhang, Paul Toren, Roy A. Jensen, John A. Taylor, Michael Jay Baltezor, Michael Dalton, John McBride, Jay Nicholas Umbreit, William McCulloch, Kathryn Vanderlaag, Joseph Wagner, Scott James Weir
Publikováno v:
Journal of Clinical Oncology. 40:TPS7069-TPS7069
TPS7069 Background: Fosciclopirox (F) is a γ-secretase inhibitor being developed for the treatment of acute myeloid leukemia (AML). Following intravenous (IV) administration, F is rapidly and completely metabolized to its active metabolite, ciclopir
Autor:
Kaitlyn McBride, Sophie Snyder
Publikováno v:
Journal of Clinical Oncology. 40:e19058-e19058
e19058 Background: The treatment landscape for patients with relapsed and refractory (RR) chronic myeloid leukemia (CML) has changed significantly in recent years, with the introduction of targeted oral anticancer therapies. Current guidelines from t